Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2023-09-11 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
Report Publication Announcement Classification · 1% confidence The document is very short (1768 characters) and explicitly states, "Attached hereto is a report on*6k* *6k11092023acc_isa.pdf*". This structure—an announcement stating that a specific report (in this case, a Form 6-K, which is a general SEC filing for foreign private issuers) is attached or published, rather than containing the full content of that report—fits the definition of a Report Publication Announcement (RPA). The document serves to notify the market about the release of another filing, not to be the filing itself (like 10-K or IR).
2023-09-11 English
FINANCIAL STATEMENTS As of June 30, 2023
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and six-month periods ended June 30, 2023. Since it provides comprehensive financial data for an interim period rather than just an announcement or a summary, it is classified as an Interim/Quarterly Report (IR). H1 2023
2023-09-02 English
FINANCIAL STATEMENTS As of June 30, 2023
Report Publication Announcement Classification · 1% confidence The document is a short notification (under 2,000 characters) from Enlivex Therapeutics Ltd to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 6-k' and provides a filename for the attachment. Per the 'MENU VS MEAL' rule, this is an announcement of a report rather than the report itself, and therefore qualifies as a Report Publication Announcement (RPA). H1 2023
2023-09-02 English
Form 6-K -Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," filed on Form 6-K for the month of August 2023. The Form 6-K itself is a general reporting requirement for foreign private issuers, often used to submit material information to the SEC that is otherwise made public in the home country. The core content attached as Exhibit 99.1 is a press release announcing the peer-reviewed publication of clinical data. Since the document is a submission to the SEC (Form 6-K) containing material news, and it does not fit the specific definitions for 10-K (Annual Report), IR (Interim Report), or ER (Earnings Release), the most appropriate general classification for a non-standard, material regulatory submission that isn't one of the other specific types is Regulatory Filings (RNS). Although it contains an earnings-related announcement (clinical data publication), the structure is that of an SEC filing (Form 6-K) submitting an exhibit (Press Release). RNS serves as the best fit for miscellaneous SEC filings that aren't 10-K, 10-Q, or specific proxy/insider forms.
2023-08-02 English
Form 6-K -Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating
Report Publication Announcement Classification · 1% confidence The document is extremely short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k02082023_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for immediate reports). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Since it is an announcement of a filing, RPA is the most appropriate classification over RNS or the underlying filing type.
2023-08-02 English
Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for Foreign Private Issuers to report material information that is otherwise required to be disclosed in their home country or to their principal exchange. The content is a press release announcing the dosing of the first patient in a Phase II trial, which is material information. Since Form 6-K is a general report for foreign private issuers and doesn't fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report), the most appropriate general regulatory filing category is 'Regulatory Filings' (RNS), as it serves as a catch-all for required SEC filings that aren't the primary periodic reports.
2023-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.